The MHRA published its 2030 Strategy on 14 October 2026. It sets out how UK regulation of medicines, devices and AI will change over the next five years, with patient safety, faster access and scientific excellence at its centre.
Much of the coverage has focused on timelines and AI. For insight and evidence teams, the more interesting story sits underneath. Several commitments depend on understanding how patients, clinicians and health systems think and behave. Here are seven areas where that understanding will matter most.
1. Patient preferences move closer to regulation
The MHRA will publish a benefit-risk framework by 2027, developed with patients and clinicians. The strategy adopts Professor Sir David Spiegelhalter’s idea of a “preference zone”: where several treatment options exist, the right choice depends on how each person weighs benefits and risks.
The framework’s detail is still to come, including how sponsor-generated preference data might be used. Companies that already understand what patients value, and which trade-offs they will accept, will be better prepared when it arrives.
2. Faster access brings insight forward
A new integrated MHRA-NICE scientific advice service will offer one entry point, one meeting and one payment, covering evidence generation, endpoints and patient populations. The aligned licensing and appraisal pathway can bring some medicines to patients three to six months earlier than sequential routes (MHRA Strategy 2030, p.18).
That moves the deadline for insight. Clinician views on meaningful endpoints, payer expectations and the size of the unmet need now shape the advice meeting itself. Research timed for the run-up to launch may arrive too late.
3. More medicines may move over the counter
The MHRA will increasingly enable reclassification where evidence supports it, prioritising applications on patient safety, unmet need and wider system benefit. It also plans clearer information to support self-care.
A successful switch depends on understanding people outside the consulting room. Can consumers judge whether a medicine is right for them? Do they understand the label? How will pharmacists advise? These questions need answering before an application goes in.
4. Product information goes digital
By 2030, the MHRA aims for all product information to be available as structured digital content, with paper and braille kept for those who need them (MHRA Strategy 2030, p.8). It also points towards more tailored communication of benefit and risk based on individual patient characteristics.
Digital formats raise new behavioural questions. Will patients find what they need? Will a personalised risk message change what they do? Testing comprehension and decision-making with real patients, before formats are fixed, is the surest way to find out.
5. Evidence that reflects everyone
The strategy acknowledges that research has not always reflected the diversity of people who use medicines and devices. The MHRA will publish Areas of Regulatory Interest to signal where better evidence is needed, starting with a new women’s health programme.
Closing those gaps starts with understanding them: why some groups take part in studies less often, and where patient journeys differ by sex, ethnicity or circumstance. Answering these early gives sponsors time to shape trial design and access plans.
6. Safety reporting and misinformation are behavioural challenges
From 2027, the MHRA will begin introducing a more conversational Yellow Card interface, and is exploring integration with the NHS App and hospital record systems (MHRA Strategy 2030, p.15). It is also stepping up work against misinformation on social media and AI platforms.
Easier tools help, and behaviour decides the outcome. Patients may not link a symptom to a medicine, and clinicians may assume someone else has reported it. Behavioural science can show what prompts a report, and what makes a trusted message stand out.
7. MedTech and AI: approval is one milestone
The MHRA aims to set the global standard for regulating MedTech and AI in healthcare by 2030. Its model relies on continuous real-world monitoring, with accountability shared between developers, deployers and health system partners. A new Early Access Service for Devices will offer time-limited, conditional approval ahead of full assessment.
For device and digital health companies, adoption depends on whether NHS organisations are ready to deploy and govern a technology, and whether clinicians trust it. Forecasting demand also gets harder when products reach the market earlier, with less evidence behind them.
What to do now
The common thread is timing. Evidence about how people weigh risk, read information, report problems and adopt new technology is moving earlier in the lifecycle and closer to regulatory decisions.
Porterhouse Insights helps pharmaceutical and MedTech teams build that understanding through patient and clinician research, payer insight and behavioural science. If the 2030 Strategy is prompting questions about your evidence plans, get in touch with the Porterhouse Insights team.
Source
Medicines and Healthcare products Regulatory Agency. MHRA Strategy 2030: Health and prosperity for all, through scientific excellence. October 2026.
Group